Plain-English translation of NCT06791512 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether adding bevacizumab and sintilimab—two medications that work differently than traditional chemotherapy—to a standard chemotherapy regimen called can improve how well the treatment works for advanced colorectal cancer. The study will compare people who receive this three-drug combination before surgery to those who receive just the standard chemotherapy alone. The goal is to see if the additional medications help shrink tumors more completely and improve long-term survival.
Standard chemotherapy has helped many colorectal cancer patients, but doctors want to know if adding newer immunotherapy and anti-cancer medications can do even better. This trial will test whether this combination approach leads to better outcomes and longer disease-free survival for patients with advanced disease.
You likely qualify if…
You likely don't qualify if…
If you qualify, you'll be randomly assigned to receive either the three-drug combination or standard chemotherapy alone. Treatment involves 6 rounds of intravenous infusions given over several weeks. After completing chemotherapy, you'll have surgery to remove the cancer. Depending on how well the treatment worked, you may receive additional chemotherapy after surgery. Throughout the trial, you'll have regular imaging scans, blood tests, and follow-up visits to monitor your progress and any side effects.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China